The Effect of Glyceraldehyde-Derived Advanced Glycation End Products on β-Tubulin-Inhibited Neurite Outgrowth in SH-SY5Y Human Neuroblastoma Cells.
Alzheimer’s disease (AD)
diabetes mellitus (DM)
glyceraldehyde (GA)
neurite outgrowth
toxic advanced glycation-end products (TAGE)
β-tubulin
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
27 Sep 2020
27 Sep 2020
Historique:
received:
11
08
2020
revised:
14
09
2020
accepted:
24
09
2020
entrez:
30
9
2020
pubmed:
1
10
2020
medline:
13
4
2021
Statut:
epublish
Résumé
Nutritional factors can affect the risk of developing neurological disorders and their rate of progression. In particular, abnormalities of carbohydrate metabolism in diabetes mellitus patients lead to an increased risk of neurological disorders such as Alzheimer's disease (AD). In this study, we investigated the relationship between nervous system disorder and the pathogenesis of AD by exposing SH-SY5Y neuroblastoma cells to glyceraldehyde (GA). We previously reported that GA-derived toxic advanced glycation end products (toxic AGEs, TAGE) induce AD-like alterations including intracellular tau phosphorylation. However, the role of TAGE and their target molecules in the pathogenesis of AD remains unclear. In this study, we investigated the target protein for TAGE by performing two-dimensional immunoblot analysis with anti-TAGE antibody and mass spectrometry and identified β-tubulin as one of the targets. GA treatment induced TAGE-β-tubulin formation and abnormal aggregation of β-tubulin, and inhibited neurite outgrowth in SH-SY5Y cells. On the other hand, glucose-derived AGEs were also involved in developing AD. However, glucose did not make abnormal aggregation of β-tubulin and did not inhibit neurite outgrowth. Understanding the underlying mechanism of TAGE-β-tubulin formation by GA and its role in neurodegeneration may aid in the development of novel therapeutics and neuroprotection strategies.
Identifiants
pubmed: 32992566
pii: nu12102958
doi: 10.3390/nu12102958
pmc: PMC7601248
pii:
doi:
Substances chimiques
Glycation End Products, Advanced
0
Tubulin
0
Glyceraldehyde
367-47-5
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Society for the Promotion of Science
ID : 19K11781
Références
J Neurochem. 2015 May;133(4):572-81
pubmed: 25708447
Cell. 1986 May 9;45(3):329-42
pubmed: 3516413
Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5710-4
pubmed: 8202552
CNS Drugs. 2003;17(1):27-45
pubmed: 12467491
Mol Med. 2000 Feb;6(2):114-25
pubmed: 10859028
Sci Rep. 2019 Feb 14;9(1):2121
pubmed: 30765817
Med Hypotheses. 2004;63(3):449-52
pubmed: 15288366
Neurobiol Dis. 2011 Sep;43(3):706-14
pubmed: 21669285
Nature. 1996 Aug 22;382(6593):685-91
pubmed: 8751438
Curr Mol Med. 2001 Jul;1(3):305-15
pubmed: 11899079
Int Rev Neurobiol. 2002;50:325-92
pubmed: 12198816
Curr Pharm Des. 2008;14(10):973-8
pubmed: 18473848
J Biol Chem. 1999 Sep 10;274(37):26503-10
pubmed: 10473611
Nat Med. 1995 Jul;1(7):693-9
pubmed: 7585153
Am J Alzheimers Dis Other Demen. 2006 Jun-Jul;21(3):197-208
pubmed: 16869341
Curr Alzheimer Res. 2004 Feb;1(1):39-46
pubmed: 15975084
J Neurosci. 2006 Sep 27;26(39):10006-19
pubmed: 17005864
Annu Rev Neurosci. 2001;24:1121-59
pubmed: 11520930
J Biochem. 1986 Jun;99(6):1807-10
pubmed: 2427509
Acta Neuropathol. 2004 Sep;108(3):189-93
pubmed: 15221334
Proc Natl Acad Sci U S A. 1989 Jul;86(14):5646-50
pubmed: 2501795
Curr Drug Targets. 2010 Nov;11(11):1468-82
pubmed: 20583971
Mol Med. 1999 Jun;5(6):393-405
pubmed: 10415164
J Neurochem. 1995 Oct;65(4):1658-64
pubmed: 7561862
J Neural Transm (Vienna). 2004 Mar;111(3):427-39
pubmed: 14991463
J Cereb Blood Flow Metab. 2003 Nov;23(11):1307-13
pubmed: 14600438
PLoS Genet. 2016 Mar 29;12(3):e1005917
pubmed: 27023670
Diagnostics (Basel). 2016 Jun 07;6(2):
pubmed: 27338481
FASEB J. 1990 Jun;4(9):2652-60
pubmed: 2189777
Biochem J. 1985 Aug 15;230(1):53-60
pubmed: 2996495
J Neuropathol Exp Neurol. 2000 Dec;59(12):1094-105
pubmed: 11138929
Proc Natl Acad Sci U S A. 1994 May 24;91(11):4766-70
pubmed: 8197133
Eur J Pharmacol. 2003 Jan 5;458(3):235-41
pubmed: 12504778
Diabetologia. 1991 Jun;34(6):387-9
pubmed: 1715829
Neurology. 1999 Dec 10;53(9):1937-42
pubmed: 10599761
Sci Rep. 2015 Aug 25;5:13313
pubmed: 26304819
World J Gastroenterol. 2015 Feb 14;21(6):1784-93
pubmed: 25684943
Diabetes Care. 2012 Dec;35(12):2618-25
pubmed: 22912424
Trends Pharmacol Sci. 2002 Jun;23(6):288-93
pubmed: 12084635